Table 2.
Patient, Tumor, and Treatment Characteristics
| Parameter | ALDH3A1 | ALDH3A2 | |||||
|---|---|---|---|---|---|---|---|
| Negative (%) | Positive (%) | p-value | Negative (%) | Positive (%) | p-value | ||
| Age | < 60 ≥ 60 |
19 (21) 21 (24) |
27 (30) 22 (25) |
0.53 | 7 (8) 11 (13) |
35 (41) 32 (38) |
0.43 |
| Gender | Male Female |
38 (43) 2 (2) |
37 (42) 12 (13) |
0.02 | 16 (19) 2 (2) |
55 (65) 12 (14) |
0.72 |
| T-stage | 0–2 3–4 |
16 (18) 24 (27) |
24 (27) 25 (28) |
0.53 | 5 (6) 13 (15) |
32 (38) 35 (41) |
0.18 |
| N-stage | 0–1 2 3 |
5 (6) 27 (30) 8 (9) |
10 (11) 32 (36) 7 (8) |
0.53 | 2 (2) 11 (13) 5 (6) |
12 (14) 45 (53) 10 (12) |
0.41 |
| Stage | 2 3 4 |
0 (0) 4 (5) 36 (40) |
4 (5) 2 (2) 43 (48) |
0.11 | 0 (0) 1 (1) 17 (20) |
4 (5) 5 (6) 58 (68) |
0.54 |
| Site | OP Others |
30 (34) 10 (11) |
25 (28) 24 (27) |
0.03 | 14 (16) 4 (5) |
38 (45) 29 (34) |
0.17 |
| HPV* | Negative Positive Inevaluable |
14 (16) 19 (21) 7 (8) |
27 (30) 15 (17) 7 (8) |
0.07 | 7 (8) 7 (8) 4 (5) |
34 (40) 24 (28) 9 (11) |
0.57 |
|
Treat- ment |
CRT Surg+RT |
37 (42) 3 (3) |
33 (37) 16 (18) |
0.004 | 16 (19) 2 (2) |
51 (60) 16 (19) |
0.34 |
CRT: Chemoradiation, RT: Radiation
*
75 patients had tumor assessable for both HPV status (p16, HPV ISH and HPV pyrosequencing) and ALDH3A1 staining & 72 patients had tumor assessable for both HPV status (p16, HPV ISH and HPV pyrosequencing) and ALDH3A2 staining